ORITAVANCIN | ORITAVANCIN | ATC J01XA05
ANTIINFECTIVES LIPOGLYCOPEPTIDE ANTIBACTERIAL TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS BINDING TO THE STEM PEPTIDE OF PEPTIDOGLYCAN PRECURSORS DURING CELL WALL BIOSYNTHESIS DISRUPTION OF BACTERIAL MEMBRANE INTEGRITY | INTRAVENOUS | Cmax 77 MICROMOLAR VD 87.6 LITER PPB 85 PERCENT Cl 0.445 LITER / HOUR HT 245 HOUR | PEPTIDOGLYCAN PRECURSORS | Unknown more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |